Test Price
2,600 AED✅ Home Collection Available
NPM1, FLT3, and CEBPA Gene Mutation Analysis in Dubai | 2600 AED | DHA Licensed
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- ✓ Clinical Guidance: Telephonic post-test clinical guidance in result interpretation by a DHA-licensed consultant medical geneticist.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Comprehensive molecular panel for acute myeloid leukemia risk stratification and targeted therapy guidance in UAE patients.
Test Overview & Methodology
This advanced genetic test analyzes NPM1, FLT3 (ITD/TKD), and CEBPA mutations in peripheral blood or bone marrow aspirate to guide acute myeloid leukemia (AML) prognosis, risk stratification, and targeted treatment selection. The panel employs targeted next-generation sequencing (NGS) with orthogonal Sanger validation to achieve the highest diagnostic accuracy for clonal heterogeneity detection.
| Feature | Our Test (NPM1/FLT3/CEBPA Panel) | Closest Alternative (Standard Sanger Only) |
|---|---|---|
| Methodology | Targeted Next-Generation Sequencing (NGS) with Sanger validation | Sanger sequencing (lower sensitivity for low-level mutations) |
| Diagnostic Precision | ≥99.9% analytical sensitivity and specificity | ~95–97% (may miss minor clones) |
| Turnaround Time | 7–8 calendar days | 10–14 days typical |
| Regulatory Compliance | DHA Licensed, ISO 9001:2015 Certified | Variable; often lacks UAE-specific accreditation |
Physician Insight & Safety Protocols
“Each mutation in the NPM1, FLT3, and CEBPA genes carries distinct prognostic weight and therapeutic implications for AML patients. This NGS-based panel provides the allelic resolution required to stratify risk and select targeted agents such as midostaurin or gilteritinib. I strongly recommend reviewing all results in conjunction with a haematologist and a clinical geneticist to ensure a fully integrated care pathway.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory – Medication Safety
Important: Do not discontinue, modify, or adjust any prescribed medication including antineoplastics, anticoagulants, or immunosuppressants without explicit consultation with your treating physician. This molecular test provides diagnostic and prognostic information and does not replace ongoing clinical monitoring or therapeutic decision-making by your haematology team.
Exclusion Criteria & Emergency Red Flags
Patient Safety Exclusion Criteria
- Informed Consent: No test may be performed on minors without written legal guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Pregnancy/Lactation: Not contraindicated, but must be ordered by an obstetric specialist with documented clinical justification.
- Severe Bleeding Risk: If platelet count <20×10⁹/L or active coagulopathy, a peripheral blood sample (non-aspirate) is preferred; bone marrow aspiration requires haematologist clearance.
- Valid Prescription: A DHA-registered physician prescription is mandatory. This test cannot be used for surgical clearance or travel certificates.
🚑 Urgent Red Flags – Seek Immediate Emergency Care (Call 998)
- Sudden severe bleeding, bruising, or petechiae
- Acute chest pain, dyspnoea, or signs of leukostasis (visual changes, confusion)
- Fever >38.3°C with absolute neutrophil count <0.5×10⁹/L (febrile neutropenia)
Patient FAQ & Clinical Guidance
1. What is the NPM1, FLT3, and CEBPA gene mutation test for AML?
This targeted next-generation sequencing panel detects clinically actionable mutations in three genes that are central to acute myeloid leukemia risk stratification and targeted therapy selection. NPM1 mutations generally confer a favourable prognosis, FLT3-ITD mutations indicate higher relapse risk and eligibility for tyrosine kinase inhibitors, and biallelic CEBPA mutations are associated with a favourable outcome in AML.
2. How should I prepare for the test?
No special fasting or dietary preparation is required. A valid DHA-registered physician prescription must be provided prior to sample collection. If a bone marrow aspirate is clinically indicated, the procedure will be performed exclusively at an accredited hospital facility. Peripheral blood collection can be arranged via VIP Mobile Phlebotomy at your home or office between 8 AM and 11 PM daily.
3. When will I receive my results, and how are they delivered?
Results are typically available within 7 to 8 calendar days after the sample reaches our DHA-licensed molecular laboratory. Reports are delivered via secure email and include a detailed interpretation signed by a consultant medical geneticist. A telephonic post-test counselling session can be arranged upon request.
4. Can this test be performed during pregnancy or while breastfeeding?
The test is not contraindicated during pregnancy or lactation; however, it must be ordered by an obstetric specialist with documented clinical justification. Peripheral blood sampling is safe, but bone marrow aspiration during pregnancy requires multidisciplinary clearance from haematology and obstetrics teams.
5. Are the results confidential and compliant with UAE data protection laws?
Yes. All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Results are only shared with the ordering physician and the patient or legal guardian.
UAE Regulatory & Data Privacy Adherence
Data Protection & Confidentiality: DNA Labs UAE adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient genetic data is encrypted, access-controlled, and processed exclusively within UAE infrastructure. No raw sequencing data is shared with third parties without explicit patient consent. Our DHA-licensed laboratory (License No. 1143) undergoes annual audits to maintain compliance with UAE healthcare data governance standards.
Clinical & Logistical Metadata
| Test Name | NPM1, FLT3, and CEBPA Gene Mutation Analysis (NGS Panel) |
| Price (AED) | 2,600 AED |
| Turnaround Time | 7–8 calendar days |
| Sample Type / Matrix | Peripheral Blood (preferred) or Bone Marrow Aspirate |
| Methodology Used | Targeted Next-Generation Sequencing (NGS) with Sanger Validation |
| ICD-10-CM Code | C92.00 (Acute myeloblastic leukemia, not having achieved remission) |
| LOINC Code | 96934-8 (NPM1 gene mutations found in Blood or Bone Marrow by Sequencing) |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians